Shanghai, China — MicroPort® announced on May 25, 2026 that Mr. Greg Holman has joined MicroPort® as Chief Commercial Officer (CCO).
As CCO, Mr. Holman will lead MicroPort®'s global commercial strategy and execution across international markets, playing a central role in advancing the company's One MicroPort strategy. He will be responsible for portfolio prioritization, brand integration, and market expansion across mature and emerging markets, with a particular focus on accelerating the growth and global footprint of GloMatrix, MicroPort's international commercial platform.
Before joining MicroPort®, Mr. Holman held senior leadership roles at Boston Scientific and Stryker across multiple therapeutic areas, and most recently served as Operating Partner at LYFE Capital. He brings over 25 years of MedTech leadership experience across the United States and Asia Pacific, including more than a decade based in China.
“I’m excited to join MicroPort® at such an important stage of its global development,” said Mr. Holman. “MicroPort® has built a strong and diversified global platform that advances patient care and provides significant growth potential. I look forward to working closely with teams across the organization to advance the One MicroPort strategy and further expand its commercial presence.”
About MicroPort Scientific Corporation (MicroPort®)
Since 1998, MicroPort® (MicroPort Scientific Corporation; HKEX: 00853) has been breaking barriers and accelerating access to life-changing solutions so that patients everywhere can live better and longer lives. As a global medical device company, MicroPort® provides solutions across ten therapeutic areas, including cardiovascular, aortic and peripheral vasculature, robotic surgery and AI, neurovascular, and orthopedics. Serving over 100 countries and 20,000 hospitals, MicroPort® provides a medical solution to a patient every 5 seconds.